- Home
- GNL vs MYGN Comparison
GNL vs MYGN Comparison
Compare GNL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNL
- MYGN
- Stock Information
- Founded
- GNL 2011
- MYGN 1991
- Country
- GNL United States
- MYGN United States
- Employees
- GNL N/A
- MYGN N/A
- Industry
- GNL Real Estate Investment Trusts
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GNL Real Estate
- MYGN Health Care
- Exchange
- GNL Nasdaq
- MYGN Nasdaq
- Market Cap
- GNL 1.7B
- MYGN 744.7M
- IPO Year
- GNL N/A
- MYGN 1995
- Fundamental
- Price
- GNL $7.43
- MYGN $5.34
- Analyst Decision
- GNL Buy
- MYGN Hold
- Analyst Count
- GNL 3
- MYGN 15
- Target Price
- GNL $9.00
- MYGN $15.14
- AVG Volume (30 Days)
- GNL 2.4M
- MYGN 1.4M
- Earning Date
- GNL 08-05-2025
- MYGN 08-05-2025
- Dividend Yield
- GNL 10.00%
- MYGN N/A
- EPS Growth
- GNL N/A
- MYGN N/A
- EPS
- GNL N/A
- MYGN N/A
- Revenue
- GNL $789,545,000.00
- MYGN $831,300,000.00
- Revenue This Year
- GNL N/A
- MYGN N/A
- Revenue Next Year
- GNL N/A
- MYGN $6.68
- P/E Ratio
- GNL N/A
- MYGN N/A
- Revenue Growth
- GNL 38.85
- MYGN 7.38
- 52 Week Low
- GNL $6.51
- MYGN $3.81
- 52 Week High
- GNL $9.11
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- GNL 41.91
- MYGN 50.85
- Support Level
- GNL $7.52
- MYGN $4.90
- Resistance Level
- GNL $7.67
- MYGN $5.83
- Average True Range (ATR)
- GNL 0.15
- MYGN 0.28
- MACD
- GNL 0.00
- MYGN 0.04
- Stochastic Oscillator
- GNL 20.95
- MYGN 54.21
About GNL Global Net Lease Inc.
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.